Page last updated: 2024-11-05
triazolam and Abstinence Syndrome, Neonatal
triazolam has been researched along with Abstinence Syndrome, Neonatal in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Attallah, A | 1 |
Seilanian, M | 1 |
Bavoux, F | 1 |
Choisy, H | 1 |
Other Studies
1 other study available for triazolam and Abstinence Syndrome, Neonatal
Article | Year |
---|---|
[Psychotropics and pregnancy. Apropos of 2 case reports: the dose of triazolam].
Topics: Apnea; Female; Half-Life; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Pregnancy; Pr | 1989 |